Skip to main content
Be The Investor
S&P 500
7,619.38+1.31%
After Hours7,585.72-0.44%
Nasdaq Composite
25,466.19+1.60%
After Hours25,240.80-0.89%
Dow Jones
52,486.49+0.49%
After Hours52,481.50-0.01%
Russell 2000
2,846.26+0.88%
After Hours2,841.48-0.17%
VIX
VIX
17.49-10.12%
Bitcoin
73,469.07-0.62%
Ethereum
2,045.67-0.39%
Solana
82.85-0.53%
Gold
3,963.30-0.93%
Silver
51.43-1.10%
Copper
6.242-0.31%
WTI Crude Oil
87.31+0.90%
US 10-Year Treasury Yield
4.998+0.28%
Home›Stocks›IAM
OverviewChartNewsFinancialsBusiness ModelCompetitorsStatisticsAnalysisEarningsValuationHoldersOptionsInsidersForecastCompareFAQ

Iambic Therapeutics Inc.

IAM
NASDAQUnited States flagUSReal-Time Price
$15.39USD
+0.60 (+4.09%)Today
$15.37-0.02 (-0.10%)After HoursLast quote · Nov 11, 2026, 7:05 PM ET · Updates paused

Investors Sentoments

Sign in to share your view.

BTI Score

BASIC required or higher

View pricing
BTI Fair Market Cap
$297.70M
Revenue-based (growth phase)
High Risk

Iambic Therapeutics Inc. (IAM) Stock News

The latest Iambic Therapeutics Inc. (IAM) news in one feed: earnings updates, analyst ratings, product launches and regulatory filings, curated and summarized by BTI.

Iambic’s HER2 Drug Shows Brain Responses in an Early Trial

IAM1363 produced systemic and intracranial responses in heavily treated HER2-driven cancers, with few severe treatment-related events at the recommended dose. The signal is notable, but it comes from a small, open-label Phase 1/1b study.

Docusign's Recovery Depends on Growth, Not Its Old High

Docusign is far below its 2021 peak, but revenue, profitability and IAM adoption have improved. The real valuation test is whether slower growth can support a durable rerating.